» Articles » PMID: 33860280

Isotope Tracing Reveals Glycolysis and Oxidative Metabolism in Childhood Tumors of Multiple Histologies

Abstract

Background: Survival among children with high-risk solid tumors remains poor. Reprogrammed metabolism promotes tumor growth and may contain therapeutic liabilities. Tumor metabolism has been assessed in adults using intra-operative C-glucose infusions. Pediatric tumors differ from adult cancers in their low mutational burden and derivation from embryonic tissues. Here we used C infusions to examine tumor metabolism in children, comparing phenotypes among tumor types and between childhood and adult cancers.

Methods: Patients recruited to study NCT03686566 received an intra-operative infusion of [U-C]glucose during tumor resection to evaluate central carbon pathways in the tumor, with concurrent metabolomics to provide a broad overview of metabolism. Differential characteristics were determined using multiple comparison tests and mixed effect analyses.

Findings: We studied 23 tumors from 22 patients. All tumors analyzed by [U-C]glucose contained labeling in glycolytic and tricarboxylic acid (TCA) cycle intermediates. Labeling in the TCA cycle indicated activity of pyruvate dehydrogenase (PDH) and pyruvate carboxylase (PC), with PDH predominating. Neuroblastomas had high lactate labeling relative to other childhood cancers and lung cancer, and were distinguished by abundant tyrosine catabolites consistent with catecholamine synthesis.

Conclusions: Intra-operative [UC]glucose infusions are safe and informative in pediatric cancer. Tumors of various histologies use glycolysis and oxidative metabolism, with subtype-selective differences evident from this small cohort. Expanding this cohort may uncover predictive biomarkers and therapeutic targets from tumor metabolism.

Funding: N.C.I grants to P.L. (R21CA220090-01A1) and R.J.D. (R35CA22044901); H.H.M.I. funding to R.J.D.; Children's Clinical Research Advisory Committee funding to K.J.

Citing Articles

The combination of exon sequencing and metabolomics to establish a molecular typing system for gastric cancer.

Yu S, Chen M, Zhu X, Chen C, Liang J, Wang H Heliyon. 2024; 10(15):e34317.

PMID: 39170180 PMC: 11336309. DOI: 10.1016/j.heliyon.2024.e34317.


Challenges of Spatially Resolved Metabolism in Cancer Research.

Lane A, Higashi R, W-M Fan T Metabolites. 2024; 14(7).

PMID: 39057706 PMC: 11278851. DOI: 10.3390/metabo14070383.


Brain development and bioenergetic changes.

Rajan A, Fame R Neurobiol Dis. 2024; 199:106550.

PMID: 38849103 PMC: 11495523. DOI: 10.1016/j.nbd.2024.106550.


Metabolic pathway analysis using stable isotopes in patients with cancer.

Bartman C, Faubert B, Rabinowitz J, DeBerardinis R Nat Rev Cancer. 2023; 23(12):863-878.

PMID: 37907620 PMC: 11161207. DOI: 10.1038/s41568-023-00632-z.


Suppression of Tumor Cell Lactate-generating Signaling Pathways Eradicates Murine PTEN/p53-deficient Aggressive-variant Prostate Cancer via Macrophage Phagocytosis.

Chaudagar K, Hieromnimon H, Kelley A, Labadie B, Shafran J, Rameshbabu S Clin Cancer Res. 2023; 29(23):4930-4940.

PMID: 37721526 PMC: 10841690. DOI: 10.1158/1078-0432.CCR-23-1441.


References
1.
Chen P, Cai L, Huffman K, Yang C, Kim J, Faubert B . Metabolic Diversity in Human Non-Small Cell Lung Cancer Cells. Mol Cell. 2019; 76(5):838-851.e5. PMC: 6898782. DOI: 10.1016/j.molcel.2019.08.028. View

2.
Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

3.
Golub D, Iyengar N, Dogra S, Wong T, Bready D, Tang K . Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics. Front Oncol. 2019; 9:417. PMC: 6534082. DOI: 10.3389/fonc.2019.00417. View

4.
Chalmers Z, Connelly C, Fabrizio D, Gay L, Ali S, Ennis R . Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017; 9(1):34. PMC: 5395719. DOI: 10.1186/s13073-017-0424-2. View

5.
Maher E, Marin-Valencia I, Bachoo R, Mashimo T, Raisanen J, Hatanpaa K . Metabolism of [U-13 C]glucose in human brain tumors in vivo. NMR Biomed. 2012; 25(11):1234-44. PMC: 3406255. DOI: 10.1002/nbm.2794. View